


NGS Genotyping Services



Genotyping Services

HLA and KIR typing

Using high throughput technology, we provide fast, accurate, and affordable high-resolution HLA and KIR typing services. Our methods enable simultaneous processing of thousands of samples, minimizing costs and turnaround time.

Typing of other target genes

We also provide high-resolution typing for the Fc receptor and MICA genes as well as chimerism testing. We are happy to work with clients to develop typing assays for other regions of interest.

HLA class I: A, B, C Exons 1 to 7
HLA class II: DPA1, DPB1, DQA1, DQB1, DRB1/3/4/5 Exons 1 to 4
KIR: Haplotypes Allelic typing
Other loci: FCR, MICA

HLA genotyping

Class I sequence based typing


- HLA-A, B, C: exons 1 through 7
- Data are phased and unambiguous to a minimum of 6 digits, up to 8 digits
- All null alleles required by ASHI and NMDP detected
- Concordance with IMGT nomenclature rulesets updated biannually

Class II sequence based typing

- DRB1/3/4/5 , DQA1, DQB1, DPA1, DPB1
- Two levels of class II typing available:
 - HLAII v1.0 exons 2 and 3
 - HLAII v2.0 exons 1 through 4
- All null alleles required by ASHI and NMDP detected
- Concordance with IMGT nomenclature rulesets updated biannually

KIR haplotyping

Using the structures of 37 KIR gene content haplotypes, we have developed a KIR haplotyping assay that can report unambiguous combinations of KIR haplotypes from an individual. Allelic typing for specific KIR loci is also available, including exons 3, 4, 5, 7, and 9.



Seven major KIR haplotypes.

Our Mission

Scisco Genetics is dedicated to:

- Providing high quality typing solutions and services for complex gene systems, including HLA and KIR.
- Enabling Next Generation technology in clinical laboratories supporting transplant programs.
- Expanding the use of the NGS platform for multiple genotyping assays including chimerism, MICA, FCR
- Continuous quality improvement in sequencing technology and software analysis tools.

Our Story

We are a Seattle-based company originally affiliated with the Fred Hutchinson Cancer Research Center. We are accredited by the American Society for Histocompatibility and Immunogenetics (ASHI), the Clinical Laboratory Improvement Amendments (CLIA) program, and the Washington State Department of Health.